Topics

Glioblastoma | Treatment | Chemotherapy | Lomustine

Home > Publications > Topics > Glioblastoma > Treatment > Chemotherapy > Lomustine

Preusser M, Kazda T, Le Rhun E, Sahm F, Smits M, Gempt J, Koekkoek JA, Monti AF, Csanadi M, Pitter JG, Bulbek H, Fournier B, Quoilin C, Gorlia T, Weller M, Minniti G; European Organisation for Research, Treatment of Cancer (EORTC) Brain Tumor Group.
Lomustine with or without reirradiation for first progression of glioblastoma, LEGATO, EORTC-2227-BTG: study protocol for a randomized phase III study.
Trials. 2024 Jun 7;25(1):366. doi: 10.1186/s13063-024-08213-7. PMID: 38849943. Interventional study protocol. ˍ

Mergen E, Landrock S, Chizzali B.
Tumor Treating Fields (TTFields) Therapy and Lomustine Chemotherapy for the Treatment of Unresectable Progressive Glioblastoma.
Case Rep Oncol. 2024 Sep 23;17(1):1056-1062. doi: 10.1159/000540669. PMID: 39474554. Case report. ˍ

*Zeyen T, Treiber A, Schneider M, Potthoff AL, Schaub C, Roever L, Layer JP, Gkika E, Vatter H, Paech D, Radbruch A, Schaefer N, Herrlinger U, Weller J.
Second-line temozolomide in first recurrent MGMT-methylated glioblastoma after lomustine/temozolomide: Efficacy and safety.
Neurooncol Adv. 2025 Apr 28;7(1):vdaf084. doi: 10.1093/noajnl/vdaf084. PMID: 40575419. Observational study. ˍ